



Virginia Commonwealth University  
VCU Scholars Compass

Hepatobiliary Cancers: Pathobiology and  
Translational Advances

Dept. of Pathology

2017

# Oncogenic NELFE Enhances MYC-induced Hepatocellular Carcinogenesis

Hien Dang  
[danghi@mail.nih.gov](mailto:danghi@mail.nih.gov)

Atsushi Takai  
*National Cancer Institute, Bethesda, United States*

Marshonna Forgues  
*National Cancer Institute, Bethesda, United States*

*See next page for additional authors*

Follow this and additional works at: [http://scholarscompass.vcu.edu/hepa\\_cancers](http://scholarscompass.vcu.edu/hepa_cancers)

 Part of the [Cancer Biology Commons](#), [Genomics Commons](#), and the [Molecular Biology Commons](#)

© The Author(s)

Downloaded from

[http://scholarscompass.vcu.edu/hepa\\_cancers/22](http://scholarscompass.vcu.edu/hepa_cancers/22)

This Abstract Accepted for Presentation is brought to you for free and open access by the Dept. of Pathology at VCU Scholars Compass. It has been accepted for inclusion in Hepatobiliary Cancers: Pathobiology and Translational Advances by an authorized administrator of VCU Scholars Compass. For more information, please contact [libcompass@vcu.edu](mailto:libcompass@vcu.edu).

---

**Authors**

Hien Dang, Atsushi Takai, Marshonna Forgues, Yosawat Pomyen, Haiwei Mou, Wen Xue, Debashish Ray, Kevn Ha, Quiad Morris, Timothy Hughes, and Xin Wei Wang

## Oncogenic NELFE Enhances MYC-induced Hepatocellular Carcinogenesis

Hien Dang<sup>1</sup>, Atsushi Takai<sup>1,a</sup>, Marshonna Forgues<sup>1</sup>, Yotsawat Pomyen, Haiwei Mou<sup>2</sup>, Wen Xue<sup>2,3</sup>, Debashish Ray<sup>4</sup>, Kevin Ha<sup>4</sup>, Quiad D. Morris<sup>4</sup>, Timothy R. Hughes<sup>4</sup>, and Xin Wei Wang<sup>1\*</sup>

<sup>1</sup>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA; <sup>2</sup>RNA Therapeutics Institute, and <sup>3</sup>Program in Molecular Medicine and Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA; <sup>4</sup>Donnelly Centre, <sup>5</sup>Department of Molecular Genetics and <sup>6</sup>Department of Computer Science, University of Toronto, Toronto, ON M5S 3E1 Canada

Transcriptomic alterations of MYC targets are associated with human cancers, including hepatocellular carcinoma (HCC). RNA binding proteins (RBPs), key regulators of RNA processing, can mediate cancer-associated transcriptomic changes often observed in HCC. In this study, we investigated the oncogenic role of the RBP Negative elongation factor E (NELFE) in HCC. NELFE mRNA is significantly elevated in HCC, which is attributed by increased gene copy number alterations. Moreover, increased NELFE gene copy is associated with poor survival. We show that oncogenic activation of NELFE promotes HCC progression by enhancing MYC signaling in two ways: 1) NELFE can directly interact with the 3'UTR of MYC target mRNAs to affect RNA stability or 2) through protein-protein interactions where NELFE modulates MYC binding to its target gene promoter regions to enhance transcription. Moreover, the overexpression of NELFE in MYC-induced HCC *Trp53<sup>fllox/fllox</sup>;alb-cre* mouse models enhanced HCC progression. We thus exploited this interplay by performing survival risk prediction analysis to develop a 20-NELFE dependent MYC target (NDMT) gene signature. This signature identified two distinctive subclasses associated with overall survival. In addition, independent cross-validation in four independent cohorts of more than 900 HCC samples demonstrate that the 20-NDMT signature is robust and predictive independently of clinical characteristics. In addition, high risk patients who have undergone transarterial chemoembolization (TACE) has a worse prognosis and increased recurrence. Together, our results suggest that oncogenic activation of NELFE supports a transcriptomic imbalance that promotes HCC progression.